gemcitabine + cisplatin + nimotuzumab + sintilimab

This drug is a **combination regimen** consisting of **gemcitabine** and **cisplatin** (commonly referred to as the "GP regimen"), in combination with **nimotuzumab**, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and **sintilimab**, a monoclonal antibody that acts as a PD-1 checkpoint inhibitor. This combination targets tumor cells through synergistic mechanisms: the GP regimen delivers cytotoxic chemotherapy, nimotuzumab disrupts EGFR-mediated signaling and enhances sensitivity to therapy, and sintilimab activates immune-mediated anti-tumor responses by blocking PD-1/PD-L1 immune checkpoints. Regimens of this type are being evaluated in clinical studies for advanced solid tumors, especially nasopharyngeal carcinoma and esophageal cancer[1][4][8]. Main mechanisms include inhibition of DNA synthesis and repair (gemcitabine), DNA crosslinking (cisplatin), EGFR pathway blockade (nimotuzumab), and enhanced anti-tumor immunity via immune checkpoint inhibition (sintilimab).

Other names

GP Regimen + nimotuzumab + sintilimab